FreeTheAI

Carlsmed Introduces aprevo Lumbar Bi-lateral Spine Fusion System Nationwide

NeutralMedium impact
CARL$14.16 −2.14%

Carlsmed, Inc. (NASDAQ:CARL) has officially made its aprevo Lumbar Bi-lateral Posterior System available across the United States. The medical device company presented the technology in San Antonio, Texas, at the 41st Annual Meeting of the North American Spine Society. Commercial availability follows a restricted trial phase that began in February 2026, with the initial surgery performed on February 10.

This system expands Carlsmed's core platform, allowing doctors to perform personalized spinal fusions via a direct posterior approach. Combining artificial intelligence modeling with clinical insights, the system builds customized three-dimensional procedure plans and patient-tailored fusion implants.

As adoption grows, market observers will track usage rates and surgical feedback. Shares of Carlsmed fell 2.10% to $14.47 following the announcement.

Key points

  • Carlsmed, Inc. (NASDAQ:CARL) rolled out its aprevo Lumbar Bi-lateral Posterior System across the U.S. spine surgery market.
  • The rollout comes after a pilot program that started in February 2026 and included a first-in-human surgery on February 10.
  • The platform incorporates AI modeling to build tailored 3D procedure plans and patient-specific fusion devices.
  • Carlsmed shares traded down 2.10% to $14.47 after the update.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What product did Carlsmed launch in the U.S.?

Carlsmed, Inc. released its aprevo Lumbar Bi-lateral Posterior System, designed for customized spinal fusion surgery.

How does the aprevo Lumbar Bi-lateral System work?

It pairs artificial intelligence software with clinical data to generate surgeon-specific 3D plans and custom implants.

When was the system first evaluated in humans?

The initial human procedure occurred on February 10, 2026, initiating a limited trial ahead of full release.